|Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.|
|PMID: 22208782 Owner: NLM Status: MEDLINE|
|BACKGROUND: ([18F])fluorodeoxyglycose-Positron Emission Tomography/Computer Tomography (([18F])FDG-PET/CT) is commonly used in staging of locally advanced esophageal cancer. Its predictive value for response to neoadjuvant therapy and survival after multimodality therapy is controversial.
METHODS: Sixty-six consecutive patients with locally advanced adenocarcinoma of the esophagus or esophagogastric junction underwent surgery after neoadjuvant chemotherapy. Staging was done prospectively with ([18F])FDG-PET/CT, before and after completion of neoadjuvant therapy. Pre- and post-therapy maximal standardized uptake values for the primary tumor (SUV1 and SUV2) were determined, and their relative change (SUV∆%) calculated. Percentage change in SUV1 was compared with histopathologic response (HPR, complete or subtotal histologic remission), disease-free- (DFS) and overall survival (OS).
RESULTS: Resection with negative margins was achieved in 60 patients. HPR rate was 14 of 66 (21.2%). Median follow-up was 16 months (range 4-72). For all patients, OS probability at three years was 59% and DFS 50%. In receiver operating characteristics (ROC) analysis, HPR was optimally predicted by a > 67% change in baseline maximal SUV (sensitivity 79% and specificity 75%). In univariate survival analysis (Cox regression proportional hazards), HPR associated with improved DFS (HR 0.208, p = 0.033) but not OS (HR 0.030, p = 0.101), SUV % > 67% associated with improved OS (HR 0.249, p = 0.027) and DFS (HR 0.383, p = 0.040). In a multivariate model (adjusted by age, sex, and ASA score), neither HPR nor SUV∆% > 67% was predictive of improved OS and DFS. However, SUV∆% as a continuous variable was an independent predictor of OS (HR 0.966, p < 0.0001) or DFS (HR 0.973, p < 0.0001).
CONCLUSION: Our results support previous results showing that ([18F])FDG-PET/CT can distinguish a group of patients with worse prognosis after neoadjuvant chemotherapy in adenocarcinoma of the esophagus or esophagogastric junction. This information could offer a new independent preoperative marker of prognosis.
|Juha T Kauppi; Niku Oksala; Jarmo A Salo; Heikki Helin; Lauri Karhumäki; Jukka Kemppainen; Eero I Sihvo; Jari V Räsänen|
|Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2012-01-02|
|Title: Acta oncologica (Stockholm, Sweden) Volume: 51 ISSN: 1651-226X ISO Abbreviation: Acta Oncol Publication Date: 2012 May|
|Created Date: 2012-05-15 Completed Date: 2012-09-27 Revised Date: 2013-05-28|
Medline Journal Info:
|Nlm Unique ID: 8709065 Medline TA: Acta Oncol Country: England|
|Languages: eng Pagination: 636-44 Citation Subset: IM|
|Helsinki University Central Hospital, Division of General Thoracic and Esophageal Surgery, Department of Cardiothoracic Surgery, Helsinki University Central Hospital, Haartmaninkatu 4, Helsinki, Finland.|
|APA/MLA Format Download EndNote Download BibTex|
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cisplatin / administration & dosage
Combined Modality Therapy
Deoxycytidine / administration & dosage, analogs & derivatives
Epirubicin / administration & dosage
Esophageal Neoplasms / diagnosis, drug therapy, mortality*
Esophagogastric Junction / drug effects, pathology, surgery
Fluorodeoxyglucose F18 / diagnostic use*
Fluorouracil / administration & dosage, analogs & derivatives
Organoplatinum Compounds / administration & dosage
Positron-Emission Tomography and Computed Tomography*
Radiopharmaceuticals / diagnostic use
Taxoids / administration & dosage
|0/Organoplatinum Compounds; 0/Radiopharmaceuticals; 0/Taxoids; 15663-27-1/Cisplatin; 15H5577CQD/docetaxel; 51-21-8/Fluorouracil; 56420-45-2/Epirubicin; 63121-00-6/oxaliplatin; 63503-12-8/Fluorodeoxyglucose F18; 6804DJ8Z9U/capecitabine; 951-77-9/Deoxycytidine|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Emission Changes Resulting from the San Pedro Bay, California Ports Truck Retirement Program.
Next Document: Effects on muscle performance of NSAID treatment with piroxicam versus placebo in geriatric patients...